par Body, Jean-Jacques
Référence Expert review of anticancer therapy, 12, 3, page (307-322)
Publication Publié, 2012-03
Référence Expert review of anticancer therapy, 12, 3, page (307-322)
Publication Publié, 2012-03
Article révisé par les pairs
Titre: |
|
Auteur: | Body, Jean-Jacques |
Informations sur la publication: | Expert review of anticancer therapy, 12, 3, page (307-322) |
Statut de publication: | Publié, 2012-03 |
Sujet CREF: | Sciences bio-médicales et agricoles |
Mots-clés: | bone metastases |
denosumab | |
skeletal-related events | |
supportive care | |
zoledronic acid | |
MeSH keywords: | Antibodies, Monoclonal -- administration & dosage -- adverse effects -- pharmacokinetics |
Antibodies, Monoclonal, Humanized | |
Biological Availability | |
Bone Density Conservation Agents -- administration & dosage -- adverse effects -- pharmacokinetics | |
Bone Neoplasms -- metabolism -- pathology -- secondary -- therapy | |
Bone Remodeling -- drug effects | |
Bone and Bones -- drug effects -- metabolism -- pathology | |
Clinical Trials as Topic | |
Diphosphonates -- administration & dosage -- adverse effects -- pharmacokinetics | |
Disease Management | |
Humans | |
Imidazoles -- administration & dosage -- adverse effects -- pharmacokinetics | |
Immunologic Factors -- administration & dosage -- adverse effects -- pharmacokinetics | |
Neoplasm Metastasis | |
Neoplasms -- pathology | |
Outcome Assessment (Health Care) | |
Palliative Care -- methods | |
RANK Ligand -- metabolism | |
Receptor Activator of Nuclear Factor-kappa B -- metabolism | |
Note générale: | Journal Article |
Review | |
SCOPUS: re.j | |
Langue: | Anglais |
Identificateurs: | urn:issn:1473-7140 |
info:doi/10.1586/era.11.204 | |
info:scp/84857852442 | |
info:pmid/22192269 |